# Acute Tubular Necrosis Management and Hemodynamic Optimization: Student Handout > **Updated March 2026 to reflect KDIGO 2026 draft guideline** ## Learning Objectives By the end of this handout, you should be able to: - Understand ATN pathophysiology and why certain interventions fail - Apply evidence-based hemodynamic targets individualized to patient characteristics - Recognize the limitations of loop diuretics in established ATN - Explain the furosemide stress test and its clinical applications - Manage electrolyte abnormalities and complications in ATN - Determine when renal replacement therapy is indicated ------------------------------------------------------------------------ ## Acute Tubular Necrosis: Ischemic Injury Pattern **Definition:** Acute tubular necrosis represents necrosis and loss of tubular epithelial cells, leading to: - Loss of tubular concentrating ability - Backleak of glomerular filtrate through damaged epithelium - Tubular obstruction from cellular debris - Marked elevation in fractional excretion of sodium (FENa \>2%) **Incidence:** Most common cause of intrinsic AKI in hospitalized patients (~45-50% of hospitalized AKI cases). **Triggers (Most Common):** 1. **Prolonged hypotension** (septic shock, cardiogenic shock) 2. **Major surgical procedures** (especially cardiac surgery) 3. **Rhabdomyolysis** (myoglobin toxicity) 4. **Contrast exposure** (now called contrast-associated AKI) 5. **Nephrotoxic drug accumulation** (aminoglycosides, vancomycin, cisplatin) ------------------------------------------------------------------------ ## Why Loop Diuretics DON’T Work in ATN: The Evidence ### The Theoretical Rationale (Why It Should Work) **Proposed Mechanisms:** 1. **Reduce metabolic demand** by blocking sodium-potassium-chloride cotransporter (NKCC) in thick ascending limb 2. **Enhance tubular flow** to prevent obstruction and backleak 3. **Improve renal blood flow** through vasodilatory effects These mechanisms are physiologically sound… yet clinical evidence shows they don’t translate to improved outcomes. ### The Clinical Reality: Systematic Evidence Against Diuretics **Meta-Analysis Findings (20 Studies, 2,608 Patients):** - Furosemide **NO IMPACT on mortality** (OR 1.015, 95% CI 0.825-1.339) - Furosemide **NO IMPACT on RRT requirement** (OR 0.947, 95% CI 0.521-1.721) - May convert oliguric to non-oliguric AKI (cosmetic change, no outcome benefit) - **More frequent electrolyte abnormalities** in diuretic-treated group **SPARK Trial (Randomized Controlled Trial, 216 Patients):** - No difference in proportion with worsening AKI (43.2% vs 37.1%) - No difference in kidney recovery (29.7% vs 42.9%) - No difference in RRT requirements (27.0% vs 28.6%) - More adverse events in furosemide group ### The Fundamental Problem: Dual Blood Pressure Effect **Critical Issue:** Loop diuretics have **opposite effects** depending on volume status: - In **fluid-overloaded patients:** May reduce intravascular volume excessively, causing renal hypoperfusion - The same drug that might help in one scenario causes harm in another - Distinguishing appropriate from excessive diuresis is clinically difficult **Clinical Pearl:** Converting oliguric AKI to non-oliguric AKI sounds beneficial but doesn’t reduce mortality or dialysis need. The underlying injury remains unchanged; urine output is simply a cosmetic change. ------------------------------------------------------------------------ ## Current Guidelines: What They Recommend **KDIGO Recommendation (Grade 1B Evidence):** - **Do NOT use furosemide prophylactically** to prevent AKI - Use diuretics **ONLY for volume overload** after appropriate management of sepsis/cardiac dysfunction - Loop diuretics have **NO ROLE in treating established ATN** **Bottom Line:** Fluid and electrolyte balance optimization is key; loop diuretics add toxicity without benefit in ATN. ### KDIGO 2026 draft Updates: Diuretics for Volume Overload in AKI **Diuretics preferred for volume overload (Rec 3.3.2, 1C):** When volume overload is present in AKI, diuretics are preferred over extracorporeal fluid removal (ultrafiltration). Reserve extracorporeal methods for diuretic-refractory cases. **Diuretic Escalation Pathway (KDIGO 2026 draft, Table 22):** | Step | Action | Details | |----|----|----| | **1. Assessment** | IV furosemide bolus | 1 mg/kg IV bolus to assess diuretic responsiveness | | **2. Escalation** | Double the dose | Increase dose if inadequate response; maximum single dose 200 mg | | **3. Synergism** | Add thiazide diuretic | Metolazone or chlorothiazide for sequential nephron blockade | | **4. Intensify** | Continuous infusion | Convert to continuous IV furosemide infusion for sustained effect | | **5. Failure** | Renal replacement therapy | If volume overload persists despite maximal diuretic therapy | **Key distinction:** This pathway is for **volume overload management**, NOT for treating ATN itself. The evidence above showing no mortality/RRT benefit for diuretics applies to diuretic use as ATN therapy. When the clinical problem is fluid overload, diuretics remain first-line. ### Furosemide Stress Test: Now Guideline-Recommended (KDIGO 2026 draft) **KDIGO 2026 draft endorses the FST (Rec 2.3.1, 2B-2C):** The furosemide stress test is now formally recommended to assess risk of AKI progression. Administer furosemide 1 mg/kg IV; urine output \<200 mL in 2 hours indicates high risk for severe AKI and RRT need. > **Evidence gap:** Current diuretic treatment trials in AKI enrolled patients based on creatinine criteria, not tubular damage biomarkers. Future trials using biomarker-guided enrollment (e.g., CXCL9, TIMP-2/IGFBP-7, urinary \[TIMP-2\]x\[IGFBP-7\]) at earlier AKI stages may reveal diuretic benefits that current creatinine-based trials could not detect. ------------------------------------------------------------------------ ## Hemodynamic Management: Personalized Blood Pressure Targets ### The Paradigm Shift: From Universal to Individualized Targets **KDIGO 2026 draft Recommendation (Rec 3.2.1, 2C):** Target MAP \>65 mmHg in critically ill patients at risk for or with AKI. Individualize based on chronic hypertension status (higher targets may be needed) and chronic hypotension (lower targets may be acceptable). **Modern Evidence:** Optimal MAP targets vary significantly based on: - **Chronic hypertension status** (most important factor — rightward-shifted autoregulation curve) - **Baseline blood pressure** (autoregulation curve shifts with chronic HTN) - **Chronic hypotension** (lower targets may be safe in patients with low baseline BP) - **AKI etiology** - **Patient age** - **Comorbidities** ### Major Trial Findings **SEPSISPAM Trial (776 septic shock patients):** **Key Findings:** - Overall: No mortality difference between MAP 65-70 vs 80-85 mmHg - **Crucial subgroup:** Chronic hypertensives (baseline SBP \>140 mmHg pre-illness) - Higher MAP (80-85) reduced RRT need by ~30% (42.2% vs 31.7%) - Number needed to treat = ~9 **Physiology Explanation:** Chronic hypertension causes **rightward shift of renal autoregulation curve**. These kidneys require higher perfusion pressures to maintain blood flow. **The 65 Trial (2,600 elderly patients ≥65 years):** - Permissive hypotension (MAP 60-65 vs usual care) showed **no harm** - Actually suggested potential mortality benefit - Challenged assumption that higher is always better ### Etiology-Specific Hemodynamic Strategies | AKI Etiology | Recommended MAP Target | Rationale | Additional Considerations | |----|----|----|----| | Sepsis, no HTN | 65-70 mmHg | Lower targets safe in this population | Avoid excessive vasopressor dose | | Sepsis + chronic HTN | 80-85 mmHg | Rightward autoregulation curve | SEPSISPAM findings | | Cardiorenal syndrome | 70-80 mmHg | Balance CO + perfusion pressure | Monitor CVP; MAP-CVP = mean perfusion pressure | | Post-cardiac surgery | \>80 mmHg | Highest sensitivity to hypotension | Each hour MAP \<65 increases AKI risk ~20% | | Hepatorenal syndrome | MAP +15 mmHg above baseline | Most aggressive target needed | Norepinephrine preferred; octreotide + albumin adjuncts | | Rhabdomyolysis | Maintain euvolemia | Hydration more important than BP per se | Avoid hypotension; aggressive fluid resuscitation | **Clinical Pearl:** The optimal blood pressure target isn’t universal—it’s personalized based on baseline hypertension history and clinical context. ### Systolic vs. Mean Arterial Pressure **Emerging Evidence:** Systolic blood pressure may provide independent prognostic information beyond MAP. **Finding:** SBP \<90-100 mmHg independently associated with severe AKI in non-critically ill patients. **Clinical Application:** Avoid SBP \<90 mmHg even if MAP technically adequate. ------------------------------------------------------------------------ ## The Furosemide Stress Test: Functional Assessment of Tubular Integrity ### What It Is and Why It Matters > **KDIGO 2026 draft status:** The FST is now formally guideline-recommended (Rec 2.3.1, 2B-2C) for assessing AKI progression risk. **Principle:** Furosemide is **actively secreted** by proximal tubular cells (not filtered). Diuretic response indicates tubular secretory capacity and structural integrity. **Clinical Significance:** In early AKI, furosemide responsiveness predicts: - Severity of kidney injury - Risk of progression to Stage 3 AKI - Need for renal replacement therapy - Mortality risk ### How to Perform the FST **Patient Selection:** - Early AKI with evidence of tubular damage (muddy brown casts, FENa \>1%, or RTEC casts) - Patient adequately resuscitated per clinical team - Stable hemodynamics **Standardized Protocol:** 1. **Baseline assessment:** Measure urine output, document baseline vital signs 2. **Furosemide administration:** - **Diuretic-naive:** 1.0 mg/kg IV bolus - **Prior exposure within 7 days:** 1.5 mg/kg IV bolus 3. **Measurement period:** Collect all urine for 2-6 hours 4. **Primary interpretation:** **2-hour urine output** (most clinically useful) ### Clinical Interpretation **Cutoff Point: 200 mL at 2 hours** | 2-Hour Urine Output | Classification | Risk Level | Prognosis | |----|----|----|----| | \>200 mL | FST-Responsive | Low risk | 13.6% require RRT; better outcomes | | 100-200 mL | Intermediate | Moderate risk | Cautious interpretation needed | | \<100 mL | FST-Nonresponsive | High risk | 75-98% require RRT; worse outcomes | ### Clinical Applications **Timing of RRT Initiation:** - FST-responsive patients: May delay RRT initiation; monitor closely - FST-nonresponsive patients: Strong signal for earlier RRT consideration **Predicting CRRT Initiation:** - FST-nonresponsive: **2.4× higher likelihood** of requiring CRRT - AUC for CRRT prediction: 0.966 (excellent discriminatory power) **Predicting Weaning from CRRT:** - Response to furosemide after CRRT cessation predicts successful RRT discontinuation ### Performance Compared to Biomarkers **Meta-Analysis Results:** - Sensitivity: 81% (vs NGAL 63%, TIMP-2/IGFBP-7 75%) - Specificity: 88% (vs NGAL 73%, TIMP-2/IGFBP-7 85%) - **Superior to traditional biomarkers** for progression prediction ------------------------------------------------------------------------ ## Supportive Management in ATN ### Fluid and Electrolyte Management **General Principles:** 1. **Goal:** Euvolemia (not volume overload, not depletion) 2. **Strategy:** Careful daily fluid balance calculation 3. **Monitoring:** Daily weights, intake/output records, clinical assessment 4. **Crystalloid choice (KDIGO 2026 draft, Rec 3.1.2, 1B):** Buffered/balanced crystalloids (lactated Ringer’s or Plasmalyte) are **preferred over 0.9% normal saline** for volume expansion in patients at risk for or with AKI. Exception: traumatic brain injury (TBI), where hypotonic solutions are contraindicated. **Specific Electrolyte Considerations:** **Hyperkalemia (Most Immediate Threat):** - **Monitor:** Daily potassium; EKG for peaked T waves - **Treat if K+ \>5.5-6.0 mEq/L or symptomatic:** - Calcium gluconate (cardiac stabilization) - Insulin + dextrose (shift intracellularly) - Albuterol (shift intracellularly) - Loop diuretics (if not anuric) + sodium polystyrene sulfonate (bind K in gut) - RRT if medical management insufficient **Hyponatremia:** - Common in ATN (dilutional from oliguric state + free water administration) - Usually mild; rarely symptomatic - Correct slowly (risk of central pontine myelinolysis if corrected too rapidly) **Metabolic Acidosis:** - Expected in ATN - Treat underlying AKI; correct as kidney function recovers - RRT if severe acidosis (pH \<7.1-7.15) impacting hemodynamics ### Medication Management **Dosing Adjustments:** - All renally-cleared medications require dose reduction - Many ICU drugs need adjustment (aminoglycosides, vancomycin, etc.) - Use renal dosing guides and therapeutic drug monitoring **Avoiding Additional Nephrotoxins:** - NSAIDs: **ABSOLUTE AVOID** in ATN - Aminoglycosides: Use only if essential; monitor levels - ACE/ARBs: May be continued if patient not oliguric; avoid in anuric phase - Contrast agents: **ABSOLUTELY AVOID** until kidney function recovered ### Nutrition **Principles:** - Provide adequate but not excessive protein (0.8-1.0 g/kg/day) - **Avoid excessive/high protein intake in AKI (KDIGO 2026 draft, PP 3.9.3):** An RCT demonstrated higher mortality in AKI patients receiving high protein loads. Excessive protein increases urea generation, worsens uremia, and may accelerate need for RRT. - **Do NOT restrict protein to prevent or delay RRT (KDIGO 2026 draft, PP 3.9.2):** While excessive protein is harmful, overly restrictive protein intake leads to malnutrition and catabolism without preventing the need for dialysis. The goal is adequate, not excessive, protein. - Avoid hypercatabolism - Monitor for electrolyte abnormalities (hyperphosphatemia, hyperkalemia) - Dialyze or filter if necessary to allow adequate nutrition ------------------------------------------------------------------------ ## Indicators for Renal Replacement Therapy Initiation **Absolute Indications (Refractory to Medical Management):** 1. **Severe hyperkalemia** (K+ \>6.0-6.5 mEq/L or EKG changes) unresponsive to medical therapy 2. **Pulmonary edema** or fluid overload unresponsive to diuretics 3. **Severe metabolic acidosis** (pH \<7.1-7.15) compromising hemodynamics 4. **Uremic symptoms:** Pericarditis, encephalopathy, seizures 5. **Anuria** for \>3-5 days with fluid overload/hyperkalemia **Relative Indications (Consider Based on Clinical Context):** - Oliguria for \>5-7 days - Rising BUN \>100 mg/dL - Inability to provide adequate nutrition without fluid overload - Need for medications requiring frequent dosing (incompatible with oliguria) **Timing Controversy:** Earlier RRT initiation (within 12-24 hours of AKI onset) shows no mortality benefit in most studies; standard approach is to delay until absolute indications develop. ------------------------------------------------------------------------ ## Monitoring During ATN Recovery **Daily Assessments:** - Vital signs (hypotension common early) - Urine output and character (darkening suggests worsening) - Fluid balance (cumulative) - Serum creatinine, BUN - Electrolytes, especially potassium - Acid-base status **Signs of Recovery:** - Increasing urine output (typically non-oliguric first) - Decreasing serum creatinine trend - Improvement in electrolyte abnormalities - Resolving uremia **Expected Timeline:** - Oligura phase: Usually 5-14 days (range 1-8 weeks) - Recovery phase: Progressive GFR improvement over weeks to months - Most patients achieve independence from RRT; some have residual CKD ------------------------------------------------------------------------ ## Practice Questions **Question 1:** A 62-year-old with chronic hypertension (baseline BP 150/90) develops septic shock. Current MAP is 68 mmHg on norepinephrine. Creatinine is rising (1.2 to 2.1). According to SEPSISPAM trial findings, which MAP target would most benefit his kidneys? A) Maintain current MAP 65-70 mmHg (standard target) B) Increase MAP to 80-85 mmHg (higher target for hypertensives) C) Reduce MAP further to 60-65 mmHg (permissive hypotension) D) MAP irrelevant; focus on urine output instead **Answer:** B) Increase MAP to 80-85 mmHg (higher target for hypertensives). The SEPSISPAM trial demonstrated that chronically hypertensive patients benefit from higher MAP targets (80-85 mmHg) compared to non-hypertensives. This patient’s baseline HTN (150/90) indicates a rightward-shifted autoregulation curve; his kidneys require higher perfusion pressures. The trial showed ~30% reduction in RRT need with this approach in hypertensives. ------------------------------------------------------------------------ **Question 2:** A 58-year-old post-CABG (day 2) has developing AKI (Cr 2.1, muddy brown casts on UA). A furosemide stress test is performed: 1.0 mg/kg IV bolus given; urine output over 2 hours is 85 mL. Which statement is most accurate? A) Patient is FST-responsive; low risk of progression B) Patient is FST-nonresponsive; high risk for progression and RRT need C) FST unreliable post-op; repeat later D) Result indicates dehydration; increase hydration **Answer:** B) Patient is FST-nonresponsive; high risk for progression and RRT need. With 85 mL urine output at 2 hours (below 200 mL threshold), this patient is FST-nonresponsive. This indicates severe tubular dysfunction and predicts ~75-98% will need RRT. The clinical team should prepare for RRT initiation and heighten hemodynamic/electrolyte monitoring. This functional assessment provides crucial prognostic information. ------------------------------------------------------------------------ **Question 3:** A 71-year-old with post-surgical ATN is anuric on day 5. Potassium is 5.8 mEq/L (flat T waves on EKG, no peaked changes yet). Current fluid status: euvolemic. Which approach best represents evidence-based practice? A) Start furosemide 40 mg IV to increase urine output and manage hyperkalemia B) Continue supportive care; RRT indications not yet met (no absolute indication) C) Initiate RRT; anuric \>5 days is indication regardless of K+ D) Give insulin + glucose IV; reassess RRT need in 24 hours **Answer:** B) Continue supportive care; RRT indications not yet met (no absolute indication). While this patient has been anuric for 5 days, he is euvolemic (no fluid overload) and his hyperkalemia is mild (K+ 5.8, no EKG changes). Furosemide (choice A) has no role in ATN and may worsen hemodynamics. RRT is indicated for absolute indications (uncontrolled hyperkalemia, fluid overload, severe acidosis). Insulin + glucose (choice D) is reasonable temporizing measure. The evidence base supports delaying RRT until absolute indications develop. This patient should be monitored closely but medical management continued. ------------------------------------------------------------------------ ## Key Takeaways 1. **Loop diuretics in ATN:** NO mortality benefit, NO RRT reduction, more complications 2. **Hemodynamic targets:** NOT universal; adjust based on chronic hypertension (80-85 mmHg if hypertensive) 3. **Furosemide stress test:** Powerful prognostic tool; \<200 mL at 2 hours = high RRT risk 4. **Core management:** Fluid/electrolyte balance, avoid additional nephrotoxins, prepare for RRT 5. **RRT indications:** Use the clinical trajectory, metabolic/fluid demand, and complications to time KRT; refractory hyperkalemia, pulmonary edema, severe acidemia, or uremic complications require urgent assessment 6. **Expected course:** Most ATN patients recover; timeline weeks to months; some residual CKD ------------------------------------------------------------------------ ## See Also ### Related Student Handouts - AKI Workup and Diagnostic Approach - AKI Biomarkers and Early Detection - Drug-Induced AKI - Dialysis Fundamentals ### Clinical Content (01-Clinical-Medicine/Nephrology) - AKI Hub - Full Clinical Reference - Essential Renal Laboratory Tests ### Atomic Notes (ZK) - CRRT Principles - RRT Modality Selection ### Butler-COM Resources - Butler COM - Nephrology Deep Dive ------------------------------------------------------------------------ ## Related Resources - Loop Diuretics in ATN: Comprehensive Review - Hemodynamics Detailed - AKI Workup and Diagnosis ------------------------------------------------------------------------ **Document Type:** Student Handout **Level:** PA/Medical Student **Created:** 2026-02-12 **Updated:** 2026-03-29 (KDIGO 2026 draft AKI/AKD guideline) **Source:** ATN management literature, SEPSISPAM trial, furosemide stress test evidence, KDIGO 2026 draft AKI/AKD guideline --- [Website version](https://urinenephrology.org/student-resources/aki/atn-management-student-handout.html) · Markdown synchronized October 3, 2026.